Trials in Baltimore, Maryland
Here are the top 10 medical studies for breast cancer in Baltimore, Maryland
Popular Filters
Phase 3 Trials
Estrogen Receptor Antagonist
Abemaciclib + Fulvestrant for Breast Cancer
Recruiting1 awardPhase 3
Baltimore, Maryland
This trial is testing a combination of two drugs, abemaciclib and fulvestrant, for treating a specific type of breast cancer that has not responded to previous treatments. Abemaciclib is taken orally and is approved for treating certain types of breast cancer. The goal is to see if this combination can help stop the cancer from growing. The study may last several years, depending on how well the treatment works for each patient.
Antibody-Drug Conjugate
Sacituzumab Govitecan + Pembrolizumab for Triple-Negative Breast Cancer
Recruiting4 awardsPhase 3
Hamilton, New Jersey
This trial compares the effectiveness of a combination of two drugs, SG and pembrolizumab, in patients with advanced triple-negative breast cancer. SG targets and kills cancer cells with chemotherapy, while pembrolizumab helps the immune system attack the cancer. Pembrolizumab has been shown to improve survival in various cancers, including triple-negative breast cancer, when used alone or in combination with other treatments.
Trials With No Placebo
Chemotherapy
AZD8205 for Endometrial Cancer
Recruiting1 awardPhase 1 & 2
Baltimore, Maryland
This trial is testing a new drug called AZD8205 to see if it can help treat advanced or spreading solid tumors. The study includes patients whose cancer is advanced or has spread and may not respond to current treatments. AZD8205 might work by stopping or slowing down the growth of cancer cells.
Tyrosine Kinase Inhibitor
BAY2927088 for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1 & 2
Fairfax, Virginia
This trial is testing a new drug called BAY2927088 for people with advanced lung cancer. The drug aims to block certain proteins that help cancer grow. Researchers want to find out how safe the drug is, the best dose to use, and how well it works in stopping cancer.
Chemotherapy
TAK-500 + Pembrolizumab for Advanced Solid Cancers
Recruiting1 awardPhase 1 & 2
Philadelphia, Pennsylvania
This trial is testing a new drug called TAK-500, alone or with pembrolizumab, in adults with advanced or spreading solid tumors. The goal is to see if TAK-500 is safe and effective in shrinking these tumors.
Flt3 Ligand
Immunotherapy + Chemotherapy for Triple Negative Breast Cancer
Recruiting1 awardPhase 1
Baltimore, Maryland
This trial tests a new combination of two immune-boosting drugs and a chemotherapy drug in patients with hard-to-treat breast cancer. The goal is to see if this combination is safe and effective at controlling the cancer.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.